Abstract | BACKGROUND: METHODS: Patients with non-metastatic, high-risk prostate cancer (T3, initial prostate specific antigen level ≥20 ng/ml, and/or Gleason score ≥8) were included. The patients were treated with carbon ion radiotherapy (the total dose from 57.6 Gy (relative biological effectiveness)/16 fractions to 66.0 Gy(relative biological effectiveness)/20 fractions), and neoadjuvant as well as adjuvant androgen deprivation therapy for at least 24 months. RESULTS: Four hundred and twenty-six patients were included with the median follow-up of 68.1 months. Of 426, 210 (49.3%), 270 (63.4%) and 251 (58.9%) had Gleason 8-10, prostate specific antigen ≥20 ng/ml and T3, respectively. The 10-year progression-free and cause-specific survival rates in Japan Cancer of the Prostate Risk Assessment 1-2 group (76.5 and 98.9%) were significantly better than those in Japan Cancer of the Prostate Risk Assessment 3-6 group (52.6 and 93.1%), (P < 0.001 and P = 0.044, respectively). The median progression-free survivals in the Japan Cancer of the Prostate Risk Assessment 1-2 and 3-6 groups were 158.9 months and 125.9 months (95% confidence interval: 108.6-143.2 months), respectively. CONCLUSIONS:
|
Authors | Koichiro Akakura, Hiroshi Tsuji, Hiroyoshi Suzuki, Tomohiko Ichikawa, Hitoshi Ishikawa, Tohru Okada, Tadashi Kamada, Masaoki Harada, Hirohiko Tsujii, Jun Shimazaki |
Journal | Japanese journal of clinical oncology
(Jpn J Clin Oncol)
Vol. 44
Issue 4
Pg. 360-5
(Apr 2014)
ISSN: 1465-3621 [Electronic] England |
PMID | 24585931
(Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Androgen Antagonists
- Antineoplastic Agents, Hormonal
- Biomarkers, Tumor
- Prostate-Specific Antigen
|
Topics |
- Aged
- Aged, 80 and over
- Androgen Antagonists
(therapeutic use)
- Antineoplastic Agents, Hormonal
(therapeutic use)
- Biomarkers, Tumor
(blood)
- Chemotherapy, Adjuvant
- Disease-Free Survival
- Heavy Ion Radiotherapy
- Humans
- Japan
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Neoadjuvant Therapy
(methods)
- Neoplasm Grading
- Predictive Value of Tests
- Prognosis
- Prostate-Specific Antigen
(blood)
- Prostatic Neoplasms
(blood, diagnosis, mortality, pathology, therapy)
- Risk Assessment
- Risk Factors
|